Strategic Collaboration Potential license and co-development opportunities with larger biotechnology and pharmaceutical players focusing on antimicrobial and vaginal health therapeutics, leveraging Hennepin Life Sciences' GML-based intravaginal formulations and patent-protected platform.

Clinical Validation Target partnerships to accelerate clinical studies and regulatory pathways, highlighting HLS’s clinical trial stage and broad-spectrum antimicrobial approach that addresses hospital acquired infections and women's health markets.

Market Entry Position for distribution partnerships in human and animal health markets, exploiting a clear interest from larger players seeking novel anti-infectives with reduced mutation potential and safety advantages.

Strategic Fundraising Leverage current funding and the potential to attract investors by demonstrating progress through clinical studies and a scalable platform, aligning with venture firms and corporate VCs focused on infectious disease and women’s health.

Targeted Outreach Prioritize engagements with mid-market biotech and contract development organizations seeking innovative antimicrobial solutions, and align messaging with large incumbents like those in the Abbots, Thermo Fisher, and similar ecosystems for potential partnerships or licensing.